The role of prostacyclin in the pathogenesis of haemolytic uraemic syndrome was evaluated in 11 children with Blood was taken from patients during the acute stage of the illness after hydration, during convalescence, and on recovery. On each occasion 4 ml was collected using an ice cold syringe and was transferred into two tubes containing EDTA (0-7 mg/ml plasma). One tube was centrifuged at 1500 g for 15 minutes at 0°C to obtain platelet-poor plasma and the other tube was centrifuged at 150 g to collect platelet-rich plasma. Both samples were then stored at -20°C for subsequent determination of prostacyclin stimulating activity in the plasma samples.
Fla, a stable metabolite of prostacyclin, were measured by radioimmunoassay during acute illness, early convalescence, and after clinical recovery. Its concentration was low during acute illness in each patient, returning to normal concentrations or above at the time of the last sample. These results suggest that plasma prostacyclin may be involved in the development of the syndrome.
Haemolytic uraemic syndrome (HUS) is one of the most important causes of acute renal failure in childhood in some regions of the world.' The association of severe shigellosis with HUS has been well established,2 3 but the pathogenesis of HUS remains unclear. Deficiency of prostacycin has been implicated in the pathogenesis of the syndrome.t1 Prostacyclin infusion has also been used in the treatment of HUS either with improvement" or equivocal results.'2 On the other hand, a recent study in five children with HUS showed that plasma 6-keto prostaglandin Fla (PGFIa), the sole stable degradation product ofprostacyclin (PGI2), was raised. 3 The present study was Blood was taken from patients during the acute stage of the illness after hydration, during convalescence, and on recovery. On each occasion 4 ml was collected using an ice cold syringe and was transferred into two tubes containing EDTA (0-7 mg/ml plasma). One tube was centrifuged at 1500 g for 15 minutes at 0°C to obtain platelet-poor plasma and the other tube was centrifuged at 150 g to collect platelet-rich plasma. Both samples were then stored at -20°C for subsequent determination of prostacyclin stimulating activity in the plasma samples.
PGI2 production was measured by the method of Moncada et al. '4 This consisted of cutting fresh rabbit aorta into fine rings, kept in tris buffer (0-05M pH 7-5) on ice for not more than two hours. The rings were then incubated in tris buffer at 22°C for five minutes and washed in ice cold buffer. This step was repeated five times to remove the basal prostacyclin activity. Then, 75 p1 of platelet- Serial numbers of patients
The plasma concentrations ofPGF(,, for the 11 patients measured during the acute stage ofillness, during convalescence, and on recovery, compared with concentrationsfrom healthy controls.
indomethacin (10 tg/ml) was added to stop further formation of prostacyclin. After removing the vascular tissue the incubants were then stored at -20°C. 6-keto PGFia, the stable non-enzymatic degradation product of prostacyclin (PGF2a), was then measured in the incubation mixtures by using a radioimmunoassay kit (New England Nuclear (NEN)). Antibody against 6-keto PGFia, supplied by NEN, has a cross reactivity with PGE2. A pilot experiment was therefore done to rule out the contribution of PGE2 Prostacyclin, a potent vasodilator and inhibitor of platelet aggregation, is produced by the endothelial tissue of the vascular system. It has now been established that endothelial damage is caused by endotoxin, due to Gram negative bacteraemia, a common finding in severe shigellosis, particularly when due to S dysenteriae type L.' The observed initial lowering of prostacyclin is probably due to its high consumption and/or low production because of the damaged endothelial lining. Subsequent increase is probably due to recovery of the vascular endothelium after clearance of the endotoxin from the circulation.
The changes observed in the coagulation parameters could either be due to the presence of fibrinogen-fibrin degradation products or deficiency of fibrinogen. We The absence of Lisch nodules virtually excludes the presence of the neurofibromatosis gene in an adult. In children with only one of the diagnostic criteria the diagnosis becomes less likely with increasing age in the continued absence of the nodules. The authors calculate that in such circumstances the risk of having the gene is 50% at birth, 15% at 9 to 14 years, and zero over the age of 20 years.
